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Abstract
Background
The chemokine CCL20 and its receptor CCR6 are putative drug targets in inflammatory
bowel disease, and CCL20 is a novel IBD predilection gene. Previous findings on the
CCL20 response in these diseases are divergent. This study was undertaken to examine
CCL20 and CCR6 during active and inactive disease, and mechanisms for CCL20 regula-
tion by the innate immune system. As TLR3 has recently emerged as a possible mediator of
CCL20 production, we hypothesised that this TLR plays an important role in enterocytic
CCL20 production.
Methods
A large microarray study on colonic pinch biopsies from active and inactive ulcerative colitis
and Crohn’s disease provided background information. CCL20 and CCR6 were localized
and their expression levels assessed in biopsies using in situ hybridization and immunohis-
tochemistry. Regulation of CCL20 was studied in the HT29 cell line using a panel of pattern
recognition receptor ligands followed by a TLR3 siRNA assay.
Results
CCL20 and CCR6mRNA abundances were increased during active inflammation (CCL20
5.4-fold in ulcerative colitis and 4.2-fold in Crohn’s disease;CCR6 1.8 and 2.0, respectively).
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CCL20 and CCR6mRNA positive immune cells in lamina propria were more numerous,
and CCL20 immunoreactivity increased massively in the epithelial cells during active inflam-
mation for both diseases. TLR3 stimulation potently induced upregulation and release of
CCL20 from HT29 cells, and TLR3 silencing reduced CCL20 mRNA and protein levels.
Conclusions
The CCL20-CCR6 axis is involved during active inflammation in both ulcerative colitis and
Crohn’s disease. The epithelial cells seem particularly involved in the CCL20 response, and
results from this study strongly suggest that the innate immune system is important for acti-
vation of the epithelium, especially through TLR3.
Introduction
Ulcerative colitis and Crohn’s disease, collectively termed inflammatory bowel disease (IBD)
affect approximately 2.2 million Europeans. Although these diseases are a huge burden for
individuals and for the society [1], their aetiology and pathogenesis are still disputed. The cur-
rent understanding of IBD is that the disease is a response to environmental factors that are
normally tolerated, such as commensal microbes, in genetically predisposed individuals. Much
of the observed genetic predisposition concerns genes related to the innate and adaptive
immune systems [2], and an important element in the efforts to understand the disease patho-
genesis is to characterize the extremely complex immune and inflammatory responses in the
diseased gut [3]. The pattern recognition receptors (PRR) play an integral part in these
responses. These are receptors of the innate immune system, which recognize specific compo-
nents of foreign material; pathogen-associated molecular patterns (PAMPs) and danger-associ-
ated molecular patterns (DAMPs). This pattern recognition results in an appropriate
regulation of the inflammatory response [4]. The toll-like receptors (TLR) were the first PRRs
to be discovered, and in humans there are 10 functional TLRs [5]. The role of PRRs in regulat-
ing inflammation through modulating cytokine production, and their contribution to the path-
ogenesis of IBD has been widely studied [6].
The chemokine CCL20 is of particular interest in IBD, due to its role in shaping gut immu-
nity [7, 8]. Moreover, CCL20 was recently identified as a susceptibility gene for IBD, adding to
the interest in its role in these diseases [9]. Targeting CCL20 and CCR6 has been suggested as
new treatment strategies in autoimmune diseases [10–12], and their role in IBD needs to be
clarified. CCL20 is a C-C-L chemokine containing the four characteristic cysteine residues with
a well-conserved relative distance, and binds exclusively to the CCR6 receptor [13]. CCL20 is
constitutively expressed by neutrophils, enterocytes, B-cells and dendritic cells, and by even
more cell types when stimulated with proinflammatory ligands, while CCR6 is expressed by T
regulatory (Treg), T helper type 17 (Th17) and immature dendritic cells, as well as B-cells [14].
CCL20 has been shown to direct Treg, Th17, B-cells and immature dendritic cells to the gut
mucosa [14–19]. There are two known aspects of CCL20 action; one is the chemokine function
as described, the second an antimicrobial effect related to the beta defensins, which are also
ligands of CCR6 [20–22]. The possible important role of TLRs in CCL20 release was shown
when Sugiura et al. found that TLR1 stimulation mediated CCL20 release [23]. TLR3 has
recently emerged as an interesting factor in IBD pathogenesis, and the production of CCL20
from gingival fibroblasts after TLR3 stimulation was the first tie between CCL20 and TLR3
[24].
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A genome-wide gene expression study on IBD colonic mucosa from our laboratory com-
bined with a meta-analysis of comparable datasets pointed out the chemokine CCL20 and its
receptor CCR6 as potentially important in the pathogenesis of these diseases [3]. The aim of
the present study was to further explore the expression of CCL20 and CCR6 in IBD by localiz-
ing these in the colonic mucosa, and also to investigate the mechanisms for CCL20 regulation.
In particular, we have investigated how a broad panel of PRR ligands regulate CCL20 synthesis
and release in colonic epithelial cells, with the hypothesis that TLR3 plays an important role in
enterocytic CCL20 production.
Materials and Methods
2.1 Ethical considerations
All subjects included in the study gave informed written consent. The study was approved by
the Regional Medical Research Ethics Committee of Central Norway (Ref. no. 5.2007.910), and
registered in the Clinical Trials Protocol Registration System (identifier NCT00516776).
2.2 Patients
Patients undergoing colonoscopy for known or suspected IBD at the Gastrointestinal Endos-
copy Unit, St. Olav’s University Hospital, Trondheim, Norway, were included in the study.
Healthy controls were recruited among persons undergoing colonoscopy due to gastrointesti-
nal symptoms with no gastrointestinal disease found (Table 1).
Pinch biopsies were collected from endoscopically assessed maximally inflamed colonic
mucosa, and normal biopsies from the hepatic flexure for all patients (n = 92). Four adjacent
biopsies were taken from each site, and either formalin-fixed or snap-frozen and stored in liq-
uid nitrogen. Diagnosis was confirmed by assessment of hematoxylin-eosin stained sections by
an expert pathologist, and samples where endoscopic and microscopic assessment differed
were excluded from the study. The subjects were divided into five groups: controls (N), active
ulcerative colitis (UCa), inactive ulcerative colitis (UCi), active Crohn’s disease (CDa) and inac-
tive Crohn’s disease (CDi). The clinical material is further described by Granlund et al [3].
2.3 Procedure
2.3.1 Transcriptome analysis and qRT-PCR confirmation. Total RNA was isolated from
snap frozen biopsies using Ambion mirVana total RNA Isolation Kit (Applied Biosystems, CA,
USA). Illumina Human HT-12 expression Bead-Chips (Illumina, San Diego, CA, USA) was
Table 1. Characteristics of subjects enrolled in microarray analysis.
Controls UC CD P
Number of subjects 20 49 23
Age, years(range) 45(19–71) 45(19–72) 36,7(20–63) n.s
Female sex (%) 9(45) 24(49) 9(39) n.s
Duration of disease, years (range) - 14(0,25–40) 7(0,2–28) n.s
5-ASA/S-ASA (%) 0 34(69) 7(30) 0.002*
Systemic corticosteroids (%) 0 9(18) 9(39) n.s
Age and duration of disease are given as mean and gender and medication as numbers. UC = Ulcerative colitis. CD = Crohn's disease.
* Signiﬁcantly higher use of 5-ASA/S-ASA in UC vs CD subjects.
doi:10.1371/journal.pone.0141710.t001
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used for global transcriptome analysis. This has been described in detail previously[3] and the
full data set is available at ArrayExpress E-MTAB-184.
Confirmative qRT-PCR was done on cDNA reverse transcribed using the High Capacity
RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA) according to the manufactur-
er’s recommendations. For CCL20, a TaqMan assay was used with the Fast Real-Time PCR
Universal PCR Master Mix and TaqMan probes (probe ID Hs01011368_m1, Life Technolo-
gies, CA, USA). CCR6 qRT-PCR analysis was done with the PerfeCta SYBR Green FastMix,
ROX (Quanta Biosciences, Gaithersburg, MD, USA), forward primer CCTAGCGGAGTTCCAG
CAAA and reverse primer: AATTCCAGCTGTCCCCTAGC (Life Technologies, Paisley, UK). All
PCR procedures were done using the StepOnePlus Real-Time PCR System and StepOne soft-
ware v. 2.1, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as housekeeping gene
(Taqman probe ID Hs99999905_m1, SYBR green primers forward: GCCGCATCTTCTTTTGCG
TC reverse: GATCTCGCTCCTGGAAGATGG, Life Technologies, Paisley, UK).
2.3.2 Histological examination, immunostaining and in situ hybridization. Four
micron sections were made from formalin-fixed colonic biopsies embedded in paraffin. Hema-
toxylin and eosin stained sections were classified as”normal”,”chronic inflammation” or”chro-
nic active inflammation” based on infiltration of neutrophils and mononuclear cells.
Immunohistochemistry (IHC) for CCL20 and CCR6 was done on randomly selected biop-
sies, using samples from five subjects from each of the groups UCa, UCi, CDa, CDi and N. Pri-
mary antibodies for both CCL20 (rabbit polyclonal antibody, cat. no. Ab9829, Abcam,
Cambridge, UK) and CCR6 (rabbit polyclonal antibody, cat.no. PA5-29015, ThermoFisher Sci-
entific, Pierce Biotechnology, Rockford, IL, USA) were used 1:400 in PBS with 1% bovine
serum albumin (BSA). Mouse antibodies (all from Dako, Glostrup, Denmark) used for deter-
mination of cells types in lamina propria were CD3 (T-cells, 1:100, M7254), CD20cy (B-cells,
1:300, M0755), CD45RO (activated T-cells, 1:300, M0742), and CD1α (immature dendritic
cells, 1:300, M3571) used with Envision + FLEXMouse [LINKER] (K8021, Dako). Rabbit poly-
clonal IgG (cat. no. ab27478, Abcam, Cambridge, UK) was used as isotype control for CCL20
and CCR6, while Mouse monoclonal IgG1 and IgG2a (cat. no. X0931 and X0943, Dako,
Glostrup, Denmark)) were used as isotype controls for CD45RO and CD1α, and CD3 and
CD20, respectively. Isotype controls were performed together with negative control (primary
antibody omitted). Secondary antibody was from Dako Real Envision (rabbit/mouse), and the
Dako EnVision peroxidase kit and Dako DAB+ chromogen (Dako, Glostrup, Denmark) were
used for detection together with hematoxylin counterstaining. In situ hybridization (ISH) for
CCL20 and CCR6mRNA was done on the same colonic biopsies as the immunohistochemical
staining, using custom probes for CCL20 and CCR6, UbC as positive control and DapB as neg-
ative control together with the RNAScope 2.0 kit (all from Advanced Cell Diagnostics, Hay-
ward, CA, USA). Procedures were according to the manufacturer’s protocol, and sections were
counterstained with hematoxylin.
The absolute and relative numbers of CCR6 staining cells were assessed by counting CCR6
positive and total number of lamina propria cells. In each section ten different areas of lamina
propria measuring at least 15,000 μm2 each were counted. All areas were selected to secure
counts over the whole depth of lamina propria, i.e. from the basement membrane of the surface
epithelium to the muscularis mucosae. This was performed for both CCR6 mRNA and protein,
and fraction of CCR6 positive epithelial cells overlying the lamina propria areas was also deter-
mined. As a measure of the amount of CCR6mRNA that is translated into protein CCR6, we
used the ratio between IHC CCR6 positive cells and ISH CCR6 positive cells. Colocalization of
mRNA and protein was assessed for CCR6 by performing ISH and IHC on serial (neighbour-
ing) sections. Serial sections were also used to analyse colocalization of CCR6 or CCL20 posi-
tive cells in lamina propria with immune cell markers.
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2.3.4 Stimulation assay in the HT29 cell line. The human epithelial cell line HT29 (colo-
rectal carcinoma, Cat. No. HTB-38, lot no. 59561256) (ATCC, Manassas, VA, USA) was used
to investigate mechanisms for expression and release of CCL20. The cells were cultured in
RPMI with 10% fetal bovine serum, glutamine 2mM and gentamicin 0.05%, at 37°C and 5%
CO2. All functional cell assays were done in the same medium, without gentamicin. Cells were
detached from the cell culture flask using trypsin/EDTA, resuspended in culture medium and
counted using a Countess Automated Cell Counter (Life Technologies, Grand Island, NY,
USA). Flat-bottom 96-well plates seeded with 20,000 cells were used for the experiments,
which were done in triplicate. The plates were incubated overnight at 37°C with 5% CO2,
before medium was removed and fresh medium applied with or without PRR ligand/cytokine.
The cells were stimulated for 20 hours, and the supernatant for all experiments harvested and
stored at -20°C until analysis.
The following ligands and concentrations were used for the cell experiments: Lipopeptide
Pam3CysSK4 (P3C) (TLR2/1) 300 ng/mL, lipomannan (LM) (TLR2/6) 30 ng/mL, lipopolysac-
charide (LPS) (TLR4) 100 ng/mL Flagellin (TLR5) 100 ng/mL, the antiviral compound R848
(TLR7/8) 100ng/mL, the peptidoglycan component muramyl dipeptide (MDP) (NOD2) 1μg/
mL (all from InvivoGen, Toulouse, France); synthetic double-stranded RNA mimic polyinosi-
nic:polycytidylic acid (poly (I:C)) (TLR3) 0.5, 5 or 50 μg/mL (Amersham Bioscience, Piscat-
away, NJ, USA), unmethylated CpG dinucleotides (TLR9) 10 μM (TibMolBiol, Berlin,
Germany), and the recombinant human cytokines IL-10 100 ng/mL and IL-1β 100 ng/mL
(both from PeproTech, Rocky Hill, NJ, USA).
2.3.5 TLR3 receptor silencing. For transfection experiments, 20,000 HT29 cells were
grown in 96 well flat bottom platens (in medium without gentamicin). Transfection was done
using Lipofectamin, RNAiMAX (Ambion, Invitrogen Dynal, Waltham, MA, USA) and TLR3
small interfering RNA (siRNA), siTLR3.6 and siTLR3.8 or a nonsilencing control RNA
(nsRNA) (all 5nM) (all from Qiagen, Venlo, Netherlands). The cells were transfected for 24
hours at 37°C with 5% CO2, followed by a 12 hour stimulation with 5μg/mL poly (I:C) before
collecting the supernatant. The cells were either assayed for viability using the MTT assay, or
lysed and kept at -80°C for isolation of RNA and qRT-PCR to confirm siRNA knockout of
TLR3.
The Ambion mirVana miRNA kit was used to isolate total RNA from the HT29 cell
lysates, and cDNA generated using the High capacity RNA-to-cDNA kit before qRT-PCR
with the TaqMan gene expression assay for TLR3 (probe ID Hs01551078_m1), CCL20
(probe ID Hs01011368_m1) and GAPDH (probe ID Hs99999905_m1). The qRT-PCR was
done on a StepOnePlus Real-Time PCR System with StepOne software v. 2.1. TLR3 and
CCL20mRNA abundance were normalized to the housekeeping gene GAPDH, and expres-
sion of both measured relative to the negative control, which were HT29 cells transfected
with nsRNA.
To assess the viability of the transfected cells 0.5mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] (Promega, Nacka, Sweden) in 10% FCS/RPMI was added to
the wells, before incubation at 37°C in 5% CO2 for 3 hours. The supernatant was then replaced
with alkaline isopropanol with 0.25% 1M NHOH and optical density measured at 570 nm after
30 min stirring using the luminometer function of the Walla Victor 3 1420 Multilabel Counter
from Perkin Elmer (Boston, MA, USA).
Supernatants from every HT29 assays were analysed for CCL20 using a commercially avail-
able enzyme-linked immunosorbent assay (ELISA) human Duo-Set (R&D, Abingdon, UK),
according to the manufacturer’s instructions.
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2.4 Statistical analysis
Microarray data analysis was done with Bioconductor [25] in the R software environment. Lin-
ear models with least squares regression and empirical Bayes moderated t-statistics was used to
determine the differential expression [26]. To adjust the p-values for multiple comparisons,
Benjamini Hochberg false discovery rate correction was performed. Data from counting of
cells were normalized, and analysed by ANOVA with multiple comparisons correction (Holm-
Sidak). The data from analysing supernatant from stimulation assays were analysed using
Kruskal-Wallis nonparametric test with Dunn’s multiple comparisons post-test. Mann-Whit-
ney U-test was used to detect group differences, while rRT-PCR results (calculated by the
ΔΔCT method) from transfection assays and colonic biopsies were analysed by paired and
unpaired t-test, respectively. Statistics were performed in GraphPad Prism 6.0 (GraphPad Soft-
ware Inc., San Diego, CA, USA).
Results
3.1 CCL20 and CCR6 mRNAs are overexpressed in active IBD
The patient characteristics and microarray results have been reported previously [27, 28]. Fig 1
shows the microarray and qRT-PCR gene expression levels for CCL20 and CCR6. Compared to
N, CCL20 is clearly overexpressed in both UCa (log2 ratio 2.43 with fold change 5.39,
p<0.001) and CDa (log2 ratio 2.08 with fold change 4.23, p<0.001). The same is seen for
CCR6 in UCa (log2 ratio 0.87 with fold change 1.83, p<0.001) and CDa (log2 ratio 1.01 with
fold change 2.01, p<0.001). In colonic biopsies from areas with no sign of active disease (UCi
and CDi), there was no significant difference in expression levels compared to N.
Five biopsies from each group were randomly selected for qRT-PCR verification of the
microarray results. These analyses confirmed the microarray data for CCL20, with significant
differences UCa vs N and CDa vs N (both p<0.01). For CCR6, qRT-PCR confirmed the UCa
vs N (p<0.05), while the CDa vs N comparison had a marginal p value of 0.06.
3.2 CCL20 and CCR6 mRNA and protein is localised to epithelium and
infiltrating cells
Five randomly chosen colonic biopsies from each group were used for IHC detection of CCL20
(Fig 2). Staining was specific and with negative isotype controls. A very weak CCL20 staining
was seen in the surface epithelial layer in inactive disease and in healthy individuals. In UCa
and CDa, on the other hand, epithelial CCL20 positivity was strong and seen throughout the
epithelium including crypts. Scattered CCL20 positive mononuclear cells, with lymphocyte
and plasma cell morphology, were also seen in the lamina propria. While these inflammatory
cells form a subepithelial band in inactive UC and CD, a massive infiltration of CCL20 positive
immune cells can be found throughout the lamina propria in active UC and CD. ISH showed a
distribution of CCL20mRNA similar to IHC findings in all groups (S1 Fig), but also showed
that mRNA localized to follicle-associated epithelium (FAE) in healthy controls (S2 Fig).
Within the groups of inactive IBD, CCR6mRNA displayed a considerable sample-to-sample
variation (Fig 3). Control biopsies from healthy individuals showed little to no CCR6 expres-
sion (S3 Fig). IHC staining showed cells positive for CCR6 protein in the lamina propria, mor-
phologically resembling lymphocytes, plasma cells, and dendritic cells. The epithelial layer had
scattered weakly positive cells, which could be unspecific since isotype and negative controls
both showed a few weakly positive epithelial cells. However, ISH positive cells were also found
in the epithelium, and the negative controls showed no staining. The amount of cells positive
for CCR6mRNA in the lamina propria were significantly higher in active disease groups
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compared to inactive and control groups, while the amount of cells positive for CCR6 protein
was significantly lower in active disease groups compared to inactive disease groups but not
healthy controls (Table 2, Fig 4). In the epithelium, the fraction of CCR6 positive cells was larg-
est in active disease groups, and this reached statistical significance for active CD compared to
healthy controls (N: 1.49±0.43%, aUC: 9.90±7.75%, aCD: 11.93±0.33%, iUC: 4.30±0.93%, iCD:
3.36±0.88%. p<0.05 aCD vs. N). To investigate this further, we performed ISH and IHC for
CCR6 mRNA and protein on serial sections (Fig 5). This showed that there is an overlap
between cells positive for CCR6 mRNA and protein in inactive disease and healthy controls,
while this is overlap is much less consistent in active disease. These results were supported by
comparing the number of IHC and ISH CCR6 positive cells in all disease groups, which showed
that the relationship between CCR6 mRNA and protein positivity is stronger in inactive than
in active disease (Table 2). In the colocalization assays for CCL20 and CCR6 protein with
immune cell markers, we found that CCL20 positive cells overlap with immune cell markers
for T-cells (CD3), activated T-cells (CD45RO) and B-cells (CD20) (Fig 6A). For CCR6 positive
cells, we found overlap with markers for immature dendritic cells (CD1α) (Fig 6B).
Fig 1. CCL20 andCCR6 gene expression in colonic biopsies. A and B:Microarray gene expression results ofCCL20 andCCR6 in colonic biopsies from
healthy controls (N), active (UCa) or inactive (UCi) ulcerative colitis, and active (CDa) or inactive (CDi) Crohn’s disease. Individual values (Log2) and mean
are plotted.C and D: qRT-PCR gene expression results ofCCL20 andCCR6 in colonic biopsies from N, Ulcerative Colitis (UC) and Crohn’s disease (CD),
n = 5 in each group. Individual values (foldchange 2-ΔΔCt) and mean are plotted. *p<0.05 versus N, **p<0.01 versus N, ***p<0.001 versus N, ###p<0.001
versus inactive disease.
doi:10.1371/journal.pone.0141710.g001
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Fig 2. Localization of CCL20 protein in colonic biopsies. Immunohistochemical staining for CCL20
protein in colonic biopsies from active (UCa) or inactive (UCi) ulcerative colitis, and active (CDa) or inactive
(CDi) Crohn’s disease. Healthy controls display CCL20 positivity similar to uninflamed biopsies and are not
shown. Scale bars as indicated. ES = Surface epithelium, EC = Crypt epithelium, LP = Lamina propria.
doi:10.1371/journal.pone.0141710.g002
Fig 3. Localization ofCCR6mRNA in colonic biopsies. In situ hybridization of CCR6mRNA in colonic
inflammatory bowel disease tissue. Sections are taken from biopsies active (UCa) or inactive (UCi) ulcerative
colitis, and active (CDa) or inactive (CDi) Crohn’s disease. High and low expression of CCR6 in inactive
disease is shown. Scale bars as indicated.
doi:10.1371/journal.pone.0141710.g003
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3.3 TLR3 stimulation potently induces CCL20 release from HT29 cells
The predominantly epithelial localization of CCL20 and induction during active inflammation
prompted us to examine possible mechanisms for this epithelial response using a panel of PRR
ligands and proinflammatory signal substances. The TLR5 ligand Flagellin, the TLR3 ligand
poly (I:C) and the proinflammatory cytokine IL-1β (Fig 7) all induced a significant release of
CCL20. The poly (I:C) response was substantial with a 446-fold increase in CCL20 release,
while the CCL20 was 9-fold increased after Flagellin stimulus. IL-1β increased CCL20 release
140-fold.
Table 2. Counting of CCR6 positive cells in Immunohistochemistry and in situ hybridization.
IHC pos. cells ISH pos. cells IHC/ISH
N 4.9±1.1 4.3±2.0 1.14±0.27
UCa 2.7±0.94 # 38.2±20.9 * # 0.071±0.025 ** ##
CDa 1.9±1.1 # 36.6±3.0 ** # 0.052±0.030 ** ##
UCi 8.7±4.3 10.8±3.8 0.81±0.40
CDi 6.7±3.0 7.2±1.6 0.93±0.41
Number of positive staining cells given in mean ± SD. N = controls, UC = Ulcerative Colitis, CD = Crohn's
Disease, a = active, i = inactive.
* p<0.05 versus control.
** p<0.01 versus control.
# p<0.05 versus inactive disease.
## p<0.01 versus inactive disease.
doi:10.1371/journal.pone.0141710.t002
Fig 4. Number of CCR6mRNA and protein positive cells in lamina propria.Number of CCR6
immunohistochemically (IHC) and in situ hybridization (ISH) positive cells in colonic biopsies from healthy
controls (N), active (UCa) or inactive (UCi) ulcerative colitis, and active (CDa) or inactive (CDi) Crohn’s
disease. Five subjects in each group for IHC, and three for ISH. CCR6 positive cells were counted in ten
15,000μm2 areas of lamina propria for each section. * p< 0.05, ** p<0.01, # p<0.05 versus corresponding
inactive disease group. Mean ± SD shown.
doi:10.1371/journal.pone.0141710.g004
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Since the cell stimulation experiments showed a potent effect of the TLR3 ligand poly (I:C),
we performed TLR3 siRNA experiments to further investigate the role of TLR3 in the CCL20
response (Fig 8). Transfection did not completely ablate TLR3 expression; TLR3 abundance
was reduced by 67.4%, 71.8% and 74.6% after treatment with the blocking agents siTLR3.6,
siTLR3.8 and the combination of the two. Expression of CCL20 was reduced by 74.8%, 63.7%
and 68.0%, and correspondingly CCL20 release from the cells was reduced by 70.7%, 47.9%
and 61.6%, but neither to the level of unstimulated controls.
The assay also showed that through poly (I:C) stimulation of the HT29 cell, TLR3 expres-
sion increased by 240%, CCL20 expression by 1798% and CCL20 release increased by 1098%.
The MTT assay showed unchanged viability for all interventions as compared to control cells
(results not shown). These results demonstrate that the CCL20 response to poly (I:C) in HT-29
cells is indeed mediated through a TLR3 pathway.
Discussion
The role of CCL20 in IBD has been investigated previously, using diverse methods and clinical
materials of variable size [29–32]. Existing knowledge is somewhat conflicting, both with
regard to whether only ulcerative colitis or Crohn’s disease, or both forms of IBD, exhibit
CCL20 involvement, and whether this is found only in active disease or not [30–32]. Data on
the regulation of CCL20 expression in the intestinal mucosa and the involvement of CCR6 is
also scarce [32]. With the CCL20-CCR6 axis emerging as a possible drug target, further studies
of these aspects of IBD pathobiology are indeed warranted [10–12].
The basis for the studies presented here is a genome-wide transcriptome analysis of a very
well controlled material of colonic mucosal samples from active and inactive ulcerative colitis
and Crohn’s disease, and healthy controls. This material is one of the largest existing, and
showed excellent performance in a meta-analysis of comparable datasets [3]. The transcrip-
tome analysis shows that expression of CCL20 is potently induced in active ulcerative colitis
and active Crohn’s disease, while expression levels in inactive disease are indistinguishable
Fig 5. CCR6 protein andmRNA in serial sections. Immunohistochemistry (IHC) and in situ hybridization
(ISH) show CCR6 protein and mRNA in colonic biopsies from active UC and inactive CD. Serial sections from
the same biopsy were used to compare the localization of mRNA and protein. Arrows show that there is no
overlap of protein and mRNA in active disease (a, b), while a clear overlap is seen in inactive disease(c).
Scale bars as indicated.
doi:10.1371/journal.pone.0141710.g005
CCL20 Enhancement in IBD Is Mediated by TLR3
PLOSONE | DOI:10.1371/journal.pone.0141710 November 4, 2015 10 / 17
from healthy controls. This is somewhat at odds with previous results, which have shown either
CCL20 overexpression in only Crohn’s disease and not ulcerative colitis [30], or also in inactive
disease [31]. We think, however, that the results presented here are very robust due to the size
and meticulous control of the clinical material. Moreover, our results are based on two modes
of mRNA quantitation (gene expression microarrays and qRT-PCR), as well as ISH, rather
than only qRT-PCR as in the previous publications. In the presented material CCR6 is also sig-
nificantly higher expressed in active ulcerative colitis and active Crohn’s disease as compared
with inactive disease or healthy controls, with no significant difference in expression level
between inactive disease and healthy individuals. In our opinion, these parallel changes in
ligand and receptor mRNA abundances further underline the robustness of the transcriptome
data.
Fig 6. Immune cell typing of CCL20 and CCR6 positive cells in serial sections. Immunohistochemistry
on serial sections from the same biopsy was performed to localize CCR6 and CCL20 positivity to different
immune cells.A: Sections from biopsies from active disease were used for CCL20 investigations. There is a
partial overlap between CCL20+ cells and CD3+, CD45RO+ and CD20+ cells (arrows a, b, c, d). B: Sections
from biopsies from inactive disease for CCR6. There is a partial overlap between CCR6+ cells and CD1α
+ cells (arrows a, b). Scale bars as indicated.
doi:10.1371/journal.pone.0141710.g006
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We further examined the localization of CCL20 and CCR6 mRNA and protein in a ran-
domly chosen subset of the mucosal samples used for gene expression studies, and we found
that CCL20 mRNA and protein were massively upregulated in the epithelial cells during active
inflammation. CCL20 expression could also be seen in infiltrating cells of the lamina propria.
In healthy controls CCL20 could be mapped mostly to follicle-associated epithelium, which is
in accordance with the findings by Kaser et al. [31]. The clear upregulation of CCL20 protein
and mRNA seen in the epithelial cells in the present study strongly indicates that epithelial
mechanisms are central in the CCL20 involvement in active IBD.
CCR6mRNA was localized to infiltrating cells and epithelium, and clearly more abundant
in active UC and CD as compared to inactive disease and controls. Unlike CCL20, the CCR6
IHC staining pattern was strikingly different from ISH, showing a lower number of IHC posi-
tive cells in active IBD than in inactive disease and normal controls. The ISH results corre-
sponded well with CCR6 gene expression measured both by microarray and qRT-PCR. The
difference between mRNA and protein expression patterns may be a consequence of ligand-
receptor complex internalization, which is a phenomenon known to occur when CCL20 binds
CCR6 [33, 34]. With the large amounts of CCL20 available in the active disease groups, it is not
unreasonable to believe that internalization leads to a false impression of fewer CCR6 positive
cells in IHC on these samples. Another possible explanation is that saturation of receptors ren-
ders the receptor protein inaccessible for the CCR6 antibody. Previous findings suggest that
CCR6 is expressed only in the epithelium of the intestinal mucosa [35], or only in infiltrating
immune cells [16]. Internalisation could explain the discrepancies in earlier studies, and their
inconsistence with our findings. Because the number of CCR6 positive cells in IHC was highest
in inactive disease, we chose to study overlap with immune cell markers here rather than in
active disease. For CCL20, the opposite was true, and colocalization assays were performed on
sections from active disease biopsies. Our results show that in lamina propria, lymphocytes are
the cells that mainly colocalize with CCL20 while immature dendritic cells colocalize with
CCR6 protein. However, none of the overlaps between immune cell markers and CCL20 or
Fig 7. CCL20 release from HT29 cells in PRR stimulation assay. Stimulation assay in the HT29 cell line.
CCL20 release after 20 hour stimulation with ligands for pattern recognition receptors (PRRs) from left to
right, TLR-1–9 and NOD2; and IL-10 and IL-1β for 20 hours. Control is medium alone. Abbreviations, PRR
ligands and concentrations used are given in material and methods. * p<0.05 versus medium. Mean ± SD is
shown.
doi:10.1371/journal.pone.0141710.g007
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CCR6 were complete, and what additional cell types produce CCR6 and CCL20 protein still
needs further investigation. IHC cannot prove whether a protein is produced in a cell or inter-
nalized through receptor binding, but our studies show that the CCL20 positivity that can be
found in the lamina propria of IBD patients is at least related to lymphocytes, and the CCR6
positivity to immature dendritic cells.
The importance of the innate immune system in the pathogenesis of IBD and how TLRs are
involved in shaping mucosal immune system is becoming more evident [6, 36]. To our knowl-
edge, involvement of the innate immune system in the regulation of human CCL20 expression
has previously not been examined thoroughly. Earlier studies have used the signalling mole-
cules IL-1α, IL-1β and TNF-α and found that these stimulate synthesis and release of CCL20
from the epithelium and from peripheral blood mononuclear cells [16, 29, 35, 37]. Sugiura
Fig 8. CCL20 gene expression and protein release in TLR3 transfection assay. A: TLR3 andCCL20
mRNA abundance in poly (I:C) stimulated HT29 cells with and without TLR3 small interfering RNA(siRNA)
transfection. Non-signalling siRNA is designated nsRNA, two different TLR3 specific siRNAs (TLR3.6 and
TLR3.8) were used alone or in combination. The cells were transfected for 24 hours using TLR3 siRNAs or
nsRNA and then stimulated with the TLR3 ligand poly (I:C) for 20 hours. Controls were unstimulated
untranfected cells, poly (I:C) stimulated cells and cells treated with nsRNA stimulated with poly (I:C). ** p< 0.01
versus nsRNA, ## p<0.01 versus unstimulated control. Mean ± SD of triplicated is shown.B: The poly (I:C)
effect on CCL20 release in HT29 cells after transfection with TLR3 siRNAs as described above. *** p< 0.001
versus nsRNA, #### p<0.0001 versus unstimulated control. Mean ± SD of triplicates is shown.
doi:10.1371/journal.pone.0141710.g008
CCL20 Enhancement in IBD Is Mediated by TLR3
PLOSONE | DOI:10.1371/journal.pone.0141710 November 4, 2015 13 / 17
et al. found that TLR1 stimulation by Yersinia Enterocolitica induce CCL20 release in intestinal
mucosa of mice and in Caco2 cells transfected with TLR1 [23]. We saw no effect of TLR1 stim-
ulation of HT29 cells. The results from our HT29 cell studies show that two members of the
TLR system stimulate CCL20 release, flagellin (TLR5) and poly (I:C) (TLR3). In particular, the
TLR3 response was very potent. Underlining this, in a series of separate studies on HT29 cells
we found that CCL20 is the fifth most potent response to poly (I:C) stimulation, mRNA abun-
dance being 48-fold increased (unpublished data). TLR3 stimulation in combination with IL-
1β has previously been shown to initiate CCL20 upregulation in human gingival fibroblasts in
periodontal disease [24], and our results indicate that this cellular mechanism can also be
important in IBD. Our novel observations, together with previous results from our laboratory
showing that TLR3 is upregulated in inflammatory bowel disease [38], strongly indicate that
this PRR may indeed play a role in activating the CCL20-CCR6 axis in inflammatory bowel dis-
ease. The ligands for TLR3 signalling in IBD are at present unknown. TLR3 senses dsRNA,
which is found during replication of most viruses, in addition to the dsRNA viruses themselves.
However, there is also evidence that TLR3 senses endogenous mRNA from damaged tissue and
might maintain inflammation independently of viral infection [39, 40]. Blocking TLR3mRNA
did not completely obliterate CCL20 expression or release from the HT29 cells, which under-
lines that there are several mechanisms for CCL20 production in intestinal epithelial cells.
Moreover, residual TLR3 expression, as siRNA assays did not block TLR3 expression entirely,
may also contribute to this. We therefore conclude that the TLR3 pathway certainly is
involved.
In conclusion, this study shows that epithelial CCL20 is potently upregulated in active ulcer-
ative colitis and Crohn’s disease, but not in inactive disease. A CCL20-CCR6 axis indeed seems
to be present, and the innate immune system is involved in CCL20 induction in the epithelium
particularly through TLR3. Human ex vivo and animal in vivomodels are needed to further
investigate the mechanism of TLR3 induced CCL20 production in the intestinal epithelium.
Supporting Information
S1 Fig. Localization of CCL20mRNA in colonic biopsies. In situ hybridization for localiza-
tion of CCL20mRNA in colonic biopsies from active (UCa), inactive (UCi) ulcerative colitis
and healthy controls. Scale bars as indicated.
(TIF)
S2 Fig. CCL20mRNA in follicle associated epithelium (FAE). In situ hybridization staining
for CCL20mRNA in colonic tissue from a healthy control, including a lymphoid follicle and
follicle-associated epithelium (FAE) staining positive for CCL20mRNA. Scale bars as indi-
cated.
(TIF)
S3 Fig. CCR6mRNA in colonic biopsy from healthy control. In situ hybridization staining
for CCR6mRNA in colonic tissue from a healthy control, showing staining pattern similar to
inactive disease groups with low positivity for CCR6mRNA (Fig 3). Scale bars as indicated.
(TIF)
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